NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board
NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board
News & Events
News
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
Empowering Futures: Celebrating Women in STEM and the Supportive Communities Behind Them
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
Nuclidium & LinaThera: Advancing Sustainable Radiopharmaceutical Development
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
Dr. Anna Kulesza joins Nuclidium
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
Cu-61: Pioneering the Future of PET Imaging with Enhanced Precision and Patient Safety
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics
NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours
NUCLIDIUM and USB selected as recipients of NETRF Investigator Award
NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumours
NUCLIDIUM receives second Innosuisse grant
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
NUCLIDIUM wins EIC Accelerator grant
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
NUCLIDIUM receives Innosuisse grant
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
Events
NUCLIDIUM at BioEquity & Swiss Biotech Days
Our CEO Leila Jaafar will present the company and our unique copper-based approach at the upcoming conferences. Meet us there!